Revenues at commercial stage biopharma company, Amryt, rose 14.6% in the third quarter of the year, compared to the same period last year.
The company took in $56.5m over the three months, compared to $49.3m dollars in the third quarter of 2020.
Much of that was driven by a 21.5% rise in revenues from metreleptin, the firm's treatment for fat use and storage condition, lipodystrophy.
"These results clearly demonstrate the strong performance of metreleptin in all regions," said Joe Wiley, CEO of Amryt Pharma.
"Overall, the results also demonstrate the strong growth we are experiencing across our business and represent our seventh consecutive quarter of positive EBITDA generation and this performance has been delivered despite the challenging COVID pandemic."
The firm made an operating loss before finance expenses, restructuring and acquisition costs of $10.1m in the quarter, up from a loss of $3.5m in the same three months in 2020.
However, gross profit rose from $22.3 in the third quarter last year to $29.3m in the same period this year.
Amryt has reaffirmed its full year guidance for revenues of $220-225m, which would represent a 20-23% growth on a year earlier.
The company also said it expects the US Food and Drug Administration will issue its decision on the approval of its lead development candidate drug, Oleogel-S10 on November 30.
Filsuvez, as it is known, is a potential treatment for the rare and serious skins condition Epidermolysis Bullosa that affects young children and adults for which there is currently no approved treatment.
"If Oleogel-S10 is approved, we will have four commercial products and the team, financial flexibility, systems and global infrastructure in place to bring Oleogel-S10 to market and to execute our significant growth plans," said Mr Wiley.
He also said that significant progress has been made in integrating Chiasma, the US business it bought earlier this year in a deal that valued the firm at $330m.
